• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

为什么戈利木单抗可用于治疗银屑病关节炎、强直性脊柱炎和类风湿关节炎？

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?

作者信息

Rossini M, Viapiana O, Orsolini G, Fracassi E, Idolazzi L, Gatti D, Adami S, Govoni M

机构信息

Rheumatology Unit, University of Verona.

出版信息

Reumatismo. 2015 Mar 31;66(4):285-303. doi: 10.4081/reumatismo.2014.799.

DOI:10.4081/reumatismo.2014.799
PMID:25829189
Abstract

Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.

摘要

戈利木单抗是一种每月皮下注射一次的抗TNF单克隆抗体，采用创新技术生产，可将免疫原性降至最低。本文回顾并更新了关于戈利木单抗治疗银屑病关节炎、强直性脊柱炎和类风湿关节炎的疗效、安全性及药物经济学方面的主要研究。

相似文献

1
Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?为什么戈利木单抗可用于治疗银屑病关节炎、强直性脊柱炎和类风湿关节炎？
Reumatismo. 2015 Mar 31;66(4):285-303. doi: 10.4081/reumatismo.2014.799.
2
Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.戈利木单抗：用于治疗类风湿性关节炎、银屑病关节炎和强直性脊柱炎。
BioDrugs. 2009;23(2):125-35. doi: 10.2165/00063030-200923020-00005.
3
Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.戈利木单抗的免疫原性及其在类风湿关节炎、银屑病关节炎和强直性脊柱炎患者中的临床相关性。
Rheumatology (Oxford). 2019 Mar 1;58(3):441-446. doi: 10.1093/rheumatology/key309.
4
[RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA].
Reumatizam. 2015;62(1):12-9.
5
Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.戈利木单抗治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎患者的患者报告结局：德国非干预性 GO-NICE 研究。
Rheumatol Int. 2019 Jan;39(1):131-140. doi: 10.1007/s00296-018-4180-4. Epub 2018 Nov 10.
6
The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.在日常临床实践中，与其他肿瘤坏死因子-α抑制剂相比，戈利木单抗治疗类风湿关节炎、强直性脊柱炎和银屑病关节炎的持久性：来自接受生物改善病情抗风湿药物治疗的斯洛文尼亚全国纵向患者登记处-BioRx.si 的观察结果。
Clin Rheumatol. 2019 Feb;38(2):297-305. doi: 10.1007/s10067-018-4324-7. Epub 2018 Oct 15.
7
Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.戈利木单抗：一种新型抗 TNF-α 药物，用于治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎。
Expert Rev Clin Immunol. 2010 Sep;6(5):721-33. doi: 10.1586/eci.10.49.
8
Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.在类风湿关节炎、银屑病关节炎或强直性脊柱炎患者中，使用人抗肿瘤坏死因子抗体戈利木单抗治疗前，γ干扰素释放试验与结核菌素皮肤试验的比较。
Arthritis Rheum. 2012 Jul;64(7):2068-77. doi: 10.1002/art.34382.
9
Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.戈利木单抗在类风湿关节炎、银屑病关节炎和强直性脊柱炎中的两年留存率：来自LORHEN注册研究的数据。
Clin Exp Rheumatol. 2017 Sep-Oct;35(5):804-809. Epub 2017 Jul 27.
10
Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.在真实临床条件下，戈利木单抗治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎患者的有效性和安全性：德国非干预性 GO-NICE 研究。
BMJ Open. 2018 Jun 14;8(6):e021082. doi: 10.1136/bmjopen-2017-021082.

引用本文的文献

1
Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment.阿巴西普、戈利木单抗和托珠单抗作为当前治疗中具有不同作用机制的选定生物原研改善病情抗风湿药。
J Clin Med. 2025 Mar 19;14(6):2107. doi: 10.3390/jcm14062107.
2
Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.长效戈利木单抗的持久性：类风湿关节炎、银屑病关节炎和强直性脊柱炎关键性 III 期临床试验汇总的 5 年治疗保留数据。
Clin Rheumatol. 2023 Dec;42(12):3397-3405. doi: 10.1007/s10067-023-06760-z. Epub 2023 Sep 26.
3
Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database.
使用美国医疗保健索赔数据库对风湿性疾病进行的戈利木单抗上市后安全性监测研究。
Clin Drug Investig. 2020 Nov;40(11):1021-1040. doi: 10.1007/s40261-020-00959-7.
4
Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry.在真实环境中与戈利木单抗长期治疗保留相关的因素：对西班牙 BIOBADASER 登记处的分析。
Rheumatol Int. 2019 Mar;39(3):509-515. doi: 10.1007/s00296-018-4177-z. Epub 2018 Oct 24.
5
Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis.戈利木单抗在免疫介导的风湿性疾病中的持续使用：对类风湿关节炎、轴性脊柱关节炎和银屑病关节炎真实世界证据的系统评价
Patient Prefer Adherence. 2017 Apr 7;11:719-729. doi: 10.2147/PPA.S128665. eCollection 2017.